BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/13/2018 6:32:35 AM | Browse: 923 | Download: 1494
Publication Name World Journal of Gastroenterology
Manuscript ID 41380
Country/Territory Spain
Received
2018-08-29 02:03
Peer-Review Started
2018-08-29 07:12
To Make the First Decision
2018-10-08 02:56
Return for Revision
2018-10-14 07:09
Revised
2018-11-18 19:01
Second Decision
2018-12-06 10:04
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2018-12-07 03:32
Articles in Press
2018-12-07 03:32
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2018-12-12 03:47
Publish the Manuscript Online
2018-12-13 06:32
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Observational Study
Article Title Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
Manuscript Source Invited Manuscript
All Author List María Fernanda Guerra Veloz, Federico Argüelles-Arias, Luisa Castro Laria, Belen Maldonado Perez, Antonio Benitez Roldan, Raul Perea Amarillo, Vicente Merino Bohorquez, Miguel Angel Calleja, Angel Caunedo Alvarez and Angel Vilches Arenas
ORCID
Author(s) ORCID Number
María Fernanda Guerra Veloz http://orcid.org/0000-0001-9708-8245
Federico Argüelles-Arias http://orcid.org/0000-0003-3646-8919
Luisa Castro Laria http://orcid.org/0000-0002-7971-9303
Belen Maldonado Perez http://orcid.org/0000-0001-8025-1472
Antonio Benitez Roldan http://orcid.org/0000-0001-5662-2544
Raul Perea Amarillo http://orcid.org/0000-0003-1447-9457
Vicente Merino Bohorquez http://orcid.org/0000-0002-0315-3411
Miguel Angel Calleja http://orcid.org/0000-0001-8449-5490
Angel Caunedo Alvarez http://orcid.org/0000-0003-4444-233X
Angel Vilches Arenas http://orcid.org/0000-0003-2197-3760
Funding Agency and Grant Number
Corresponding Author Federico Argüelles-Arias, PhD, Doctor, Professor, Department of Gastroenterology, University Hospital Virgen Macarena, Dr. Fedriani 3, seville 41007, Spain. farguelles@telefonica.net
Key Words Crohn’s disease; Ulcerative colitis; CT-P13; Inflammatory bowel disease; Biosimilar agent; Infliximab original; Efficacy
Core Tip Although not strictly necessary, there are few studies comparing efficacy and safety of the switch from infliximab original (Remicade®) to infliximab biosimilar CT-P13 vs the maintenance of the original infliximab. For this reason, we presented a comparative study with the original infliximab. Our observational study demonstrates the real-life clinical results of efficacy and safety of inflixi­mab original and the efficacy and safety after switching from original infliximab to infliximab biosimilar CT-P13 at the 12 mo follow-up. Our results demonstrate there is no statistical difference in remission rate, secondary loss of response or adverse events between both therapies.
Publish Date 2018-12-13 06:32
Citation Guerra Veloz MF, Argüelles-Arias F, Castro Laria L, Maldonado Pérez B, Benítez Roldán A, Perea Amarillo R, Merino Bohórquez V, Calleja MA, Caunedo Álvarez Á, Vilches Arenas Á. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World J Gastroenterol 2018; 24(46): 5288-5296
URL https://www.wjgnet.com/1007-9327/full/v24/i46/5288.htm
DOI https://dx.doi.org/10.3748/wjg.v24.i46.5288
Full Article (PDF) WJG-24-5288.pdf
Full Article (Word) WJG-24-5288.docx
STROBE Statement 41380-STROBE statement.pdf
Manuscript File 41380-Review.docx
Answering Reviewers 41380-Answering reviewers.pdf
Audio Core Tip 41380-Audio core tip.m4a
Biostatistics Review Certificate 41380-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form 41380-Conflict-of-interest statement.pdf
Copyright License Agreement 41380-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s) 41380-Informed consent statement.pdf
Institutional Review Board Approval Form or Document 41380-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate 41380-Language certificate.pdf
Peer-review Report 41380-Peer-review(s).pdf
Scientific Misconduct Check 41380-Scientific misconduct check.pdf
Scientific Editor Work List 41380-Scientific editor work list.pdf